WuXi XDC Cayman (HKG:2268) completed the sale of 24.13 million new shares to its controlling shareholder WuXi Biologics (HKG:2269), according to a Thursday Hong Kong bourse filing.
The shares were sold at HK$58.85 each for HK$1.41 billion in net proceeds.
WuXi XDC previously said it will use about 90% of the proceeds to expand capacity at its Singapore and Wuxi sites, with the balance for working capital and general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.